OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $24.7778.

KIDS has been the topic of several research analyst reports. Canaccord Genuity Group set a $25.00 target price on shares of OrthoPediatrics in a report on Friday, April 24th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research reiterated a “buy” rating and issued a $24.00 price target on shares of OrthoPediatrics in a report on Friday, May 1st. Truist Financial lifted their price target on shares of OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Friday, July 17th.

OrthoPediatrics Stock Up 0.4%

NASDAQ KIDS opened at $20.19 on Friday. OrthoPediatrics has a 12 month low of $14.42 and a 12 month high of $22.80. The company has a current ratio of 5.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.29. The stock has a market cap of $518.48 million, a PE ratio of -12.02 and a beta of 0.99. The stock’s 50 day moving average is $18.97 and its 200 day moving average is $17.80.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. The business had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. Research analysts predict that OrthoPediatrics will post -1.13 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Several large investors have recently made changes to their positions in the company. Millennium Management LLC lifted its position in shares of OrthoPediatrics by 48.0% in the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after buying an additional 452,840 shares in the last quarter. Vanguard Group Inc. grew its holdings in OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after buying an additional 10,927 shares in the last quarter. Granahan Investment Management LLC grew its holdings in OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares in the last quarter. Wasatch Advisors LP increased its stake in OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after acquiring an additional 186,357 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in OrthoPediatrics by 6.0% in the 3rd quarter. Marshall Wace LLP now owns 444,320 shares of the company’s stock worth $8,233,000 after acquiring an additional 25,191 shares during the last quarter. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.